著者
Nasser Malekpour Alamdari Siamak Afaghi Fatemeh Sadat Rahimi Farzad Esmaeili Tarki Sasan Tavana Alireza Zali Mohammad Fathi Sara Besharat Leyla Bagheri Fatemeh Pourmotahari Seyed Sina Naghibi Irvani Ali Dabbagh Seyed Ali Mousavi
出版者
Tohoku University Medical Press
雑誌
The Tohoku Journal of Experimental Medicine (ISSN:00408727)
巻号頁・発行日
vol.252, no.1, pp.73-84, 2020 (Released:2020-09-09)
参考文献数
49

The Coronavirus Disease 2019 (COVID-19) pandemic has killed many people worldwide since December 2019, and Iran has been among the most affected countries. In this retrospective study, we aimed to determine the prognostic factors associated with mortality in COVID-19 patients by analyzing 396 survived and 63 non-survived patients in Shahid Modarres Hospital, Tehran, Iran, from January 30th until April 5th, 2020. As the results, the BMI > 35 (p = 0.0003), lung cancer (p = 0.007), chronic kidney disease (p = 0.002), Immunocompromised condition (p = 0.003), and diabetes (p = 0.018) were more frequently observed in the expired group. The history of statins use was more common in the discharged group (p = 0.002), while there was no significant difference in the drug history of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, aspirin, and/or steroids, and in the past-year influenza vaccination. Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. In conclusion, the patients with older age and higher BMI with lymphopenia, hypomagnesemia, elevated CRP and/or raised creatinine on admission are at higher risk of mortality due to the COVID-19 infection, which requires the physicians to use timely and strong therapeutic measures for such patients.

言及状況

外部データベース (DOI)

Twitter (3507 users, 3586 posts, 4685 favorites)

@am_emet @Na67882206 @mau_adrien @PRUDENTSIMONE @Arna3Arnaud @guyteissier @Carolinebharati @raoult_didier Une petite sélection (il y en a d'autres, il suffit de chercher) https://t.co/C4bt6UnLaF https://t.co/PGhRLSE3rh https://t.co/PL7YIGnGc1 https://t.co/AufGXYLC0W https://t.co/1gbajBbCib https://t.co/OgCqWmFPOE https://t.co/y91DarZfDP https://t.co/Nc7UzkSEZ0
@Monstercoyliar @FreeBeeCee @angela_bower @RCPrentice @Mwforhr @jkellyca @Death_is_final @StopVaxxedLies @BeckyJohnson222 @Shared_facts @GeoffSchuler @HupperichWerner @100Dianne @mcfunny @ianfmusgrave @JohnMallery10 @carlsmythe @KayVonPaul @barryjohnreid21 @Kelly24403519 @seek_not @VileThePro @ShallowHal9 @DreadPirRob42 @haveaconcern @Landau_18901 @KixerP @RisetteMD @LauraDekker1 @SMcwoof @Gardeniagal4 @EdDarrell @WhereJuliet @Dadsonworldwide @JaneEOpie @ghoppe @organicdot @CovidMillion @MonstaTofu @Ephesians6__12 @ale_battini @BoastIra @Chris_F_Carson @_mamadeb @MacBaird13 @markmcdougall13 @peterre76976220 @Kathmarval @KatLaRue7 https://t.co/3WccJ8t9ZP
@roropapa4 @pouite @MisterOz5 @Tsarorius @Karl_Peter_Abel @zenutopia1 @raoult_didier @CNEWS @Senat @DgCostagliola @yazdanpanah_y Et lisez l’étude iranienne, partie traitement. Là où Raoult dit « ça marche », eux disent qu’ils ne peuvent pas conclure. https://t.co/VZpuBnrDnz
@BolkonskyG @T_Fiolet @michelseydur @dd42433071 @PrrGss @DariusRochebin @raoult_didier @LCI https://t.co/YWcnkh8zTT https://t.co/PL7YIGFh3z https://t.co/PGhRLSms2H https://t.co/C4bt6U69M5
@kemaltahaoglu @kalacakk https://t.co/Fd1Ub7TsC1
@DeryaTR_ @DHsyn4633 https://t.co/jXtAoCQBAv https://t.co/Fd1Ub7TsC1
@mcfunny @Mwforhr @BeckyJohnson222 @VileThePro @Shared_facts @barryjohnreid21 @GeoffSchuler @HupperichWerner @Death_is_final @100Dianne @angela_bower @ianfmusgrave @JohnMallery10 @carlsmythe @KayVonPaul @Kelly24403519 @seek_not @jkellyca @ShallowHal9 @StopVaxxedLies @DreadPirRob42 @haveaconcern @Landau_18901 @KixerP @RisetteMD @LauraDekker1 @SMcwoof @Gardeniagal4 @EdDarrell @RCPrentice @WhereJuliet @Dadsonworldwide @JaneEOpie @ghoppe @organicdot @CovidMillion @MonstaTofu @Monstercoyliar @Ephesians6__12 @ale_battini @BoastIra @Chris_F_Carson @_mamadeb @MacBaird13 @markmcdougall13 @peterre76976220 @Kathmarval @KatLaRue7 @chaoticsx2 @SVaxhole https://t.co/3WccJ8t9ZP
@cherry_crusader @MartineWonner @EChabriere @IHU_Marseille @Laissonslespre1 @raoult_didier @info_libertes @Mediapart @france_soir @Rue89Strasbourg @franceinter "Il n'y aurait qu'en France que l'hydroxychloroquine ne fonctionne pas ? En Iran (459 patients) et en Arabie Saoudite (5541 patients), effet très favorable de l'hydroxychloroquine sur la mortalité." https://t.co/r7w14lX0L0 https://t.co/yH94T9TSoU
@boutaour Il n'y aurait qu'en France que l'hydroxychloroquine ne fonctionne pas ? En Iran (459 patients) et en Arabie Saoudite (5541 patients), effet très favorable de l'hydroxychloroquine sur la mortalité. https://t.co/9hMhGh1KCO https://t.co/aVTQBbfvvB
Il n'y aurait qu'en France que l'hydroxychloroquine ne fonctionne pas ? En Iran (459 patients) et en Arabie Saoudite (5541 patients), effet très favorable de l'hydroxychloroquine sur la mortalité. https://t.co/2gwx9R6rUq https://t.co/vJj95KLFMh
Il n'y aurait qu'en France que l'hydroxychloroquine ne fonctionne pas ? En Iran (459 patients) et en Arabie Saoudite (5541 patients), effet très favorable de l'hydroxychloroquine sur la mortalité. https://t.co/gx6WCI64Wf https://t.co/67fD9i3Hkk
El estudio observacional iraní publicado sobre la mortalidad en pacientes hospitalizados con COVID-19 (n = 459) muestra un beneficio de supervivencia estadísticamente significativo para los tratados con hidroxicoloroquina. https://t.co/M4wJSxCWfc covid.
Published Iranian observational study of mortality in hospitalized COVID-19 patients (n=459) shows a statistically significant survival benefit for those treated with hydroxycholoroquine. https://t.co/TDQiYFQl4I https://t.co/WFVipu95tM

収集済み URL リスト